FMP

FMP

Enter

ZTS - Zoetis Inc.

photo-url-https://images.financialmodelingprep.com/symbol/ZTS.png

Zoetis Inc.

ZTS

NYSE

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.

157.44 USD

1.79 (1.14%)

ZTS Financial Statements

Year

2024

2023

2022

2021

Total Revenue

9.26B

8.54B

8.08B

7.78B

Cost of Revenue

2.72B

2.71B

2.45B

2.3B

Gross Profit

6.54B

5.83B

5.63B

5.47B

Operating Expenses

3.15B

2.77B

2.7B

2.67B

Research and Development

686M

614M

539M

508M

Selling, General & Administrative Expenses

2.32B

2.15B

2.01B

2B

Selling & Marketing Expenses

0

281M

287M

292M

General & Administrative Expenses

0

1.87B

1.72B

1.71B

Other Expenses

141M

0

150M

161M

Operating Income

3.39B

3.07B

2.89B

2.75B

Total Other Income/Expenses Net

-259M

-133M

-430M

-484M

Income Before Tax

3.13B

2.94B

2.66B

2.49B

Income Tax

637M

596M

545M

454M

Net Income

2.49B

2.34B

2.11B

2.04B

Basic EPS

5.47

5.08

4.51

4.29

EPS Diluted

5.47

5.07

4.49

4.27

Basic Average Shares

454.2M

461.17M

468.89M

474.35M

Diluted Average Shares

454.85M

462.27M

470.38M

476.72M

EBITDA

3.87B

3.69B

3.36B

3.17B

Retained Earning Schedule

Year

2024

2023

2022

2021

Retained Earnings (Previous Year)

10.29B

8.67B

7.19B

5.66B

Net Income

2.49B

2.34B

2.11B

2.04B

Stock Repurchases

-1.86B

-1.09B

-1.59B

-743M

Dividend Paid

-786M

-692M

-611M

-474M

Retained Earnings

11.97B

10.29B

8.67B

7.19B

Other Distributions

-971M

-157M

-723M

310M

PPE Schedule

Year

2024

2023

2022

2021

Gross PPE

3.61B

3.43B

2.97B

2.6B

Annual Depreciation

497M

491M

465M

448M

Capital Expenditure

-655M

-732M

-586M

-477M

Net PPE

3.77B

3.67B

3.09B

2.63B

Intangible and Goodwill Schedule

Year

2024

2023

2022

2021

Acquisitions and Adjustments

-35M

13M

64M

-12M

Goodwill (Previous Year)

2.76B

2.75B

2.68B

2.69B

Goodwill

2.72B

2.76B

2.75B

2.68B

All figures are in USD.

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2025 © Financial Modeling Prep